In the first quarter of 2025, the Krka Group reported a revenue of €522.1 million, marking a 7% increase compared to the previous year. The net profit reached €152.5 million, showing a significant rise of 54% year on year. These results were discussed during the regular meeting of Krka's Supervisory Board.

Jože Colarič, President of the Management Board and Chief Executive, stated: "The Krka Group continues to operate successfully in 2025. In the first quarter of 2025, we generated the highest sales and net profit to date. Sales increased in five of six sales regions, most key markets, and across all product and service groups." He also noted that four new prescription pharmaceuticals were added to their product portfolio and highlighted an 8% increase in product and service sales with over a 50% rise in net profit.

Colarič attributed this growth partly to changes in the value of the Russian rouble affecting their net financial result. He emphasized that robust cash flow from operating activities allows for smooth settlement of operating liabilities, investments, and maintaining their long-term dividend policy.

The Supervisory and Management Boards have proposed a dividend payment of €8.25 gross per share for 2024, which is a 10% increase from last year. Shareholders are expected to vote on this proposal at the upcoming Annual General Meeting scheduled for July 10, 2025.

Additionally, Krka continues its investment in Krka Pharma Private Limited—a joint venture with Laurus Labs Ltd., established in Hyderabad, India—in April 2024 where they hold a majority stake.